Brief: Novartis Remind Data At Eaaci Show Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria (Cindu)
12/06/2026 10:46
BRIEF-Novartis Remind Data At Eaaci Show Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria (Cindu) June 12 (Reuters) - NOVARTIS AG NOVN.S:
NOVARTIS REMIND DATA AT EAACI SHOW RHAPSIDO® POTENTIAL AS FIRST TARGETED THERAPY FOR CHRONIC INDUCIBLE URTICARIA (CINDU)
Source text: ID:nGNEbgLNG4
Further company coverage: NOVN.S
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Novartis AG
See all newsBrief: Novartis Remind Data At Eaaci Show Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria (Cindu)
Swiss stocks - Factors to watch on June 12
Swiss pharma hub Basel frets over population cap threat
Novartis says rare muscle disease drug shows promise in early trial
Live Markets: Europe at half-time: countdown to the ECB's 'insurance hike'